DE69612198T2 - Eine impfstoffzusammensetzung,bestehend aus einem polysaccharid antigen-konjugatadsorbiert an aluminiumphosphat - Google Patents

Eine impfstoffzusammensetzung,bestehend aus einem polysaccharid antigen-konjugatadsorbiert an aluminiumphosphat

Info

Publication number
DE69612198T2
DE69612198T2 DE69612198T DE69612198T DE69612198T2 DE 69612198 T2 DE69612198 T2 DE 69612198T2 DE 69612198 T DE69612198 T DE 69612198T DE 69612198 T DE69612198 T DE 69612198T DE 69612198 T2 DE69612198 T2 DE 69612198T2
Authority
DE
Germany
Prior art keywords
vaccine composition
composition consisting
aluminum phosphate
polysaccharide antigen
antigen conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69612198T
Other languages
English (en)
Other versions
DE69612198D1 (de
DE69612198T3 (de
Inventor
Julien Peetermans
Pierre Hauser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69612198(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en
Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en
Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en
Priority claimed from GBGB9606032.2A external-priority patent/GB9606032D0/en
Application filed by GlaxoSmithKline Biologicals SA, SmithKline Beecham Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE69612198D1 publication Critical patent/DE69612198D1/de
Publication of DE69612198T2 publication Critical patent/DE69612198T2/de
Application granted granted Critical
Publication of DE69612198T3 publication Critical patent/DE69612198T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69612198T 1995-06-23 1996-06-19 Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat Expired - Lifetime DE69612198T3 (de)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9512827.8A GB9512827D0 (en) 1995-06-23 1995-06-23 Vaccines
GB9512827 1995-06-23
GB9513443 1995-07-01
GBGB9513443.3A GB9513443D0 (en) 1995-07-01 1995-07-01 Vaccines
GBGB9525657.4A GB9525657D0 (en) 1995-12-15 1995-12-15 Vaccines
GB9525657 1995-12-15
GBGB9606032.2A GB9606032D0 (en) 1996-03-22 1996-03-22 Vaccines
GB9606032 1996-03-22
PCT/EP1996/002690 WO1997000697A1 (en) 1995-06-23 1996-06-19 A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
EP96922871A EP0833662B2 (de) 1995-06-23 1996-06-19 Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat

Publications (3)

Publication Number Publication Date
DE69612198D1 DE69612198D1 (de) 2001-04-26
DE69612198T2 true DE69612198T2 (de) 2001-11-08
DE69612198T3 DE69612198T3 (de) 2011-08-18

Family

ID=27451299

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69612198T Expired - Lifetime DE69612198T3 (de) 1995-06-23 1996-06-19 Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat
DE69637950T Expired - Lifetime DE69637950D1 (de) 1995-06-23 1996-06-19 Impfstoff bestehend aus auf Aluminium-Phosphat adsorbiertem, konjugiertem Polysaccharid Antigen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69637950T Expired - Lifetime DE69637950D1 (de) 1995-06-23 1996-06-19 Impfstoff bestehend aus auf Aluminium-Phosphat adsorbiertem, konjugiertem Polysaccharid Antigen

Country Status (36)

Country Link
EP (2) EP1082965B1 (de)
JP (2) JP4850987B2 (de)
KR (1) KR100425929B1 (de)
CN (1) CN1146444C (de)
AP (1) AP812A (de)
AR (1) AR003006A1 (de)
AT (2) ATE199831T1 (de)
AU (1) AU696338B2 (de)
BG (1) BG62720B1 (de)
BR (1) BRPI9609414B8 (de)
CA (1) CA2222455C (de)
CY (1) CY2297B1 (de)
CZ (1) CZ288908B6 (de)
DE (2) DE69612198T3 (de)
DK (2) DK1082965T3 (de)
DZ (1) DZ2055A1 (de)
EA (1) EA199700413A1 (de)
EG (1) EG25924A (de)
ES (2) ES2157447T5 (de)
GR (1) GR3036088T3 (de)
HK (2) HK1009764A1 (de)
HU (1) HU224514B1 (de)
IL (1) IL122588A (de)
MA (1) MA23918A1 (de)
MY (1) MY114786A (de)
NO (1) NO325169B1 (de)
NZ (1) NZ312132A (de)
OA (1) OA10646A (de)
PE (1) PE11298A1 (de)
PL (1) PL184872B1 (de)
PT (2) PT833662E (de)
SI (2) SI0833662T2 (de)
SK (1) SK176197A3 (de)
TR (1) TR199701682T1 (de)
TW (1) TW467746B (de)
WO (1) WO1997000697A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biolog Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US6468765B1 (en) 1995-04-21 2002-10-22 Human Genome Sciences, Inc. Selected Haemophilus influenzae Rd polynucleotides and polypeptides
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
PL184872B1 (pl) * 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
CA2259415A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
AU750587B2 (en) * 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
SK288007B6 (sk) 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
MXPA03006561A (es) 2001-01-23 2004-10-15 Aventis Pasteur Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
JP4697706B2 (ja) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
ES2280809T3 (es) 2002-11-01 2007-09-16 Glaxosmithkline Biologicals S.A. Composicion inmunogenica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2191844B1 (de) 2003-01-30 2014-03-05 Novartis AG Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CN103405761A (zh) 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2346314T3 (es) * 2003-10-02 2010-10-14 Glaxosmithkline Biolog Sa Antigenos de b. pertussis y uso de los mismos en vacunacion.
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
EP2272531A3 (de) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration von Meningokokkenkonjugatimpfstoff
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
BRPI0610297A2 (pt) 2005-04-18 2010-06-08 Novartis Vaccines & Diagnostic expressão de antìgeno de superfìcie de vìrus da hepatite b para a preparação de vacina
US9931397B2 (en) 2005-06-27 2018-04-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
PT2004225E (pt) 2006-03-22 2012-05-30 Novartis Ag Regimes para imunização com conjugados meningocócicos
PT2097102E (pt) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
US20100074918A1 (en) 2007-05-02 2010-03-25 Jan Poolman Vaccine
RU2009149359A (ru) 2007-06-04 2011-07-20 Новартис АГ (CH) Состав вакцин против менингита
FR2918671B1 (fr) * 2007-07-10 2010-10-15 Sanofi Pasteur Milieu de culture d'haemophilus influenzae type b.
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
TW201043267A (en) * 2009-03-19 2010-12-16 Intervet Int Bv In situ constituting a vaccine for administration to a predetermined herd of animals
EP2411048B1 (de) * 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvantierendes meningokokken-faktor-h-bindungsprotein
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
EP2661277A2 (de) 2011-01-05 2013-11-13 Bharat Biotech International Limited Siebenwertiger kombinationsimpfstoff
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
EP2592137A1 (de) 2011-11-11 2013-05-15 Novartis AG Fermentierungsmedium ohne Bestandteile tierischen Ursprungs zur Herstellung von Diphtherie-Impfstoffen zur menschlichen Impfung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
ES2653261T3 (es) 2012-02-01 2018-02-06 Glaxosmithkline Biologicals S.A. Procedimiento de fermentación
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
JP2015525794A (ja) 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
BE1022008B1 (fr) 2013-08-05 2016-02-03 Glaxosmithkline Biologicals S.A. Compositions immunogenes combinees
WO2018156465A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
EP3655024A1 (de) 2017-07-18 2020-05-27 Serum Institute of India Private Limited Immunogene zusammensetzung mit verbesserter stabilität, erhöhter immunogenität und verminderter reaktivität und verfahren zur herstellung davon
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020236973A1 (en) 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
CN111658617A (zh) * 2019-10-14 2020-09-15 四川大学 一种含铝佐剂疫苗的冻干制剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
DE69113564T2 (de) * 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biolog Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
DE69323264D1 (de) * 1992-10-27 1999-03-11 American Cyanamid Co Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
PL184872B1 (pl) * 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie

Also Published As

Publication number Publication date
WO1997000697A1 (en) 1997-01-09
EP0833662B1 (de) 2001-03-21
JP4850987B2 (ja) 2012-01-11
AU696338B2 (en) 1998-09-10
KR100425929B1 (ko) 2004-05-31
TW467746B (en) 2001-12-11
ES2325301T3 (es) 2009-09-01
CZ418997A3 (cs) 1998-06-17
NO325169B1 (no) 2008-02-11
BG102146A (en) 1998-10-30
EP0833662B2 (de) 2011-01-26
HU224514B1 (hu) 2005-10-28
NZ312132A (en) 1999-04-29
CA2222455C (en) 2013-05-28
ES2157447T3 (es) 2001-08-16
DE69637950D1 (de) 2009-07-23
PE11298A1 (es) 1998-03-20
MY114786A (en) 2003-01-31
AR003006A1 (es) 1998-05-27
SI1082965T1 (sl) 2009-08-31
AU6359196A (en) 1997-01-22
ES2157447T5 (es) 2011-04-29
JPH11507935A (ja) 1999-07-13
CA2222455A1 (en) 1997-01-09
SK176197A3 (en) 1998-07-08
DK1082965T3 (da) 2009-07-27
DE69612198D1 (de) 2001-04-26
DZ2055A1 (fr) 2002-10-20
AP812A (en) 2000-02-24
BR9609414B1 (pt) 2013-11-19
CN1146444C (zh) 2004-04-21
KR19990028336A (ko) 1999-04-15
MA23918A1 (fr) 1996-12-31
BG62720B1 (bg) 2000-06-30
NO976035D0 (no) 1997-12-22
BRPI9609414B8 (pt) 2021-05-25
SI0833662T2 (sl) 2011-06-30
EP0833662A1 (de) 1998-04-08
MX9710521A (es) 1998-08-30
ATE199831T1 (de) 2001-04-15
PT1082965E (pt) 2009-07-01
HUP9900061A3 (en) 2000-03-28
HK1009764A1 (en) 1999-06-11
IL122588A0 (en) 1998-06-15
IL122588A (en) 2001-12-23
PL184872B1 (pl) 2003-01-31
CN1188418A (zh) 1998-07-22
HUP9900061A1 (hu) 1999-04-28
ATE433329T1 (de) 2009-06-15
CZ288908B6 (cs) 2001-09-12
OA10646A (en) 2002-09-18
SI0833662T1 (en) 2001-12-31
HK1037516A1 (en) 2002-02-15
EA199700413A1 (ru) 1998-08-27
EP1082965A1 (de) 2001-03-14
DK0833662T3 (da) 2001-07-09
EG25924A (en) 2012-10-22
PT833662E (pt) 2001-09-28
DK0833662T4 (da) 2011-02-28
BR9609414A (pt) 1999-05-18
NO976035L (no) 1998-02-16
JP2008120833A (ja) 2008-05-29
GR3036088T3 (en) 2001-09-28
EP1082965B1 (de) 2009-06-10
PL324242A1 (en) 1998-05-11
TR199701682T1 (xx) 1998-06-22
DE69612198T3 (de) 2011-08-18
AP9701159A0 (en) 1998-01-31
CY2297B1 (en) 2003-07-04

Similar Documents

Publication Publication Date Title
DE69612198T2 (de) Eine impfstoffzusammensetzung,bestehend aus einem polysaccharid antigen-konjugatadsorbiert an aluminiumphosphat
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
BG97198A (bg) Диалкокси-пиридинил-бензимидазолови производни, метод за получаването им и тяхното фармацевтично приложение
FI951572A0 (fi) Menetelmä pienmolekyylisten polysakkaridieetterien valmistamiseksi
FI19991917A (fi) Parannettu meningokokki-polysakkaridikonjugaattirokote
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
DE69231663D1 (de) Konjugate bestehend aus polysaccharid und protein
DE599775T1 (de) Gelstiftantipersperantien und Verfahren zu seiner Herstellung.
DE69030649D1 (de) Polysaccharide derivate sowie trennmittel
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
DE69706596D1 (de) Farbstoff-markiertes Antikörperkonjugat und Verfahren zu seiner Herstellung
CA2337667A1 (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
ITRM950143V0 (it) Fermo per evitare la dilatazione di contenitori comprimibili, dopo la loro compressione.
DE3750642D1 (de) Verfahren und Zusammensetzungen betreffend regressions-assoziierte Antigene.
DE69622415D1 (de) 12H-Dibenzo[d,g][1,3]dioxocin Derivate
FR2731355B1 (fr) Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant
ITRM910385A1 (it) Vaccini utilizzanti eritrociti come veicoli di antigeni
KR970006264A (ko) 신규한 6-치환-5, 8-디옥시-1, 4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도
FR2733230B1 (fr) Nouveaux derives d'ornithine, procede de preparation, utilisation et composition les comprenant
BR1100937A (pt) Composto, processos para sua preparação e obtenção, e, composições farmacêuticas
FR2753968B1 (fr) Nouvelles heteroaryloxyethylamines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
FI972988A0 (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
HU9500986D0 (en) Agent and preparation for external application, practically useful to cure dermatological and immunological diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8366 Restricted maintained after opposition proceedings